Quoted Text
Prescription for peril?
"He said he didn't know why he felt so bad. He said 'Sometimes you feel like you can't take it.' "
By CATHLEEN F. CROWLEY, Staff writer
First published: Saturday, March 29, 2008
QUEENSBURY -- Seventeen days after Cody Miller started taking medication for his seasonal allergy, the 15-year-old killed himself.
Miller's parents believe their son's medication, Singulair, caused his death in August.
Kate and David Miller of Queensbury appeared on national morning television shows on Friday to tell their story and warn other parents about psychological side effects they believe are linked to Singulair. The drug, which is prescribed for asthma and allergies, is manufactured by Merck & Co.
The U.S. Food and Drug Administration announced Thursday that it is investigating the possible connection between Singulair and suicide. In October, Merck added "suicidality" to the drug's label; Merck has changed Singulair's label and safety information three other times over the past 12 months to include side effects of anxiousness, depression and tremors.
Singulair, Merck's top-selling drug, earned the company $4.3 billion last year. It has been on the market 10 years. In clinical trials with more than 11,000 patients, one suicide attempt was reported, according to Merck, but the company said it was not necessarily linked to the Singulair.
"Essentially, (the FDA) has not drawn any conclusions about Singulair and suicide; it's just an issue that they are going to look at," said Ron Rogers, a Merck spokesman.
Cody Miller was the only child of Kate Miller, a hair salon owner, and David Miller, a state correction officer.
The Millers questioned their doctor when he changed Cody's allergy medication from Allegra to Singulair. They researched side effects on Merck's Web site and called the doctor again before filling the prescription.
"He said it was a perfectly safe drug with minimal side effects," Kate Miller said.
The first week on Singulair, Cody had leg cramps. The Millers didn't think much of it: Cody was working a summer job at a fun park and spent a lot of time on his feet.
"The second week, he was just not himself. He was very agitated, anxious, really having a hard time," Kate Miller said.
Cody was sweating profusely and couldn't calm down.
"He has never had any issues with emotional problems or depression or anything," his mother said.
Cody was heading into his sophomore year at Queensbury High School. He was nearly 6 feet tall with an athletic build. He played football and enjoyed hiking, skiing, wrestling and jumping on the family's trampoline.
The Millers attributed Cody's behavior to the normal turmoil of the teenage years.
On the day Cody killed himself, he came home from work agitated.
"He was hot and tired. His eyes were very red and very empty, like a person that has been so sleep deprived," Kate Miller said.
His parents sat him down to talk.
"He said he didn't know why he felt so bad. He said 'Sometimes you feel like you can't take it,' " Kate Miller said. "I said 'What is going on? What is the matter?' His legs were shaking. He was very, very nervous and upset."
Cody took a nap on their porch. The family ordered pizza and Kate Miller sent Cody upstairs for a shower when he woke up."Instead of taking a shower, he hung himself," said Kate Miller, as her voice broke with emotion.
As the family searched for answers after Cody's suicide, they dissected his computer for clues and found nothing to suggest he was unhappy. They found a Web site of testimonials about psychological side effects experienced by adults and children taking Singulair.
Almost simultaneously, Merck in October added "suicidality" to Singulair's drug information pamphlet. The term encompasses a range of behaviors from suicidal thoughts to attempted suicide and suicide.
The Millers contacted state Sen. Elizabeth Little, R-Queensbury, and U.S. Rep. Kirsten Gillibrand, D-Greenport. They reached out to the media and will soon tell their story to the FDA.
"It's very difficult to do this. This child was our only child," Kate Miller said. "We are fighting a fight to get information to people. It's not right when they tell you the benefits outweigh the risks and they don't tell you what the risks are."
Cathleen F. Crowley can be reached at 454-5348, or by e-mail at ccrowley@timesunion.com.